Ohio State Navbar

Research

William E. Carson, III, M.D.


410 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-6306

Email: carson.77@osu.edu

 

Current OSU Appointments

Professor, Surgical Oncology

Professor, SBS-Cancer Biology & Genetics

Physician, FGP-Surgical Oncology

 

Academic Advising

2007 - present Kristan Guenterberg,, The Ohio State University. PGY 3, Department of Surgery
2008 - present Neela Bhave,, The Ohio State University. Fellow, Human Cancer Genetics
2009 - present Valerie Grignol,, The Ohio State University. T32 fellow, Human Cancer Genetics
2010 - present Joseph Markowtiz,, The Ohio State University. T32 Fellow, Tumor Immunology
2010 - present Eric Leudke,, The Ohio State University. T32 Fellow, Human Cancer Genetics
2010 - present Sara Martin, The Ohio State University. T32 Fellow, Tumor Immunology
2013 - present Amanda Harper, The Ohio State University. The MD/PhD Medical Scientist Training Program
2013 - present Elizabeth McMichael, The Ohio State University. Graduate Program, IBGP
2013 - present Nicholas Latchana,, The Ohio State University. T32 Fellow, Tumor Immunology
1994 - 1996 Melanie Marien, The Ohio State University. Graduated 1996. Natural Sciences
1998 - 1999 Timothy Bakalakos,, The Ohio State University. Fellow, Department of Surgery
1998 - 2000 Julie Dierksheide, The Ohio State University. Graduated 2000. Pathology
1999 - 2001 Mirella Anghelina,, The Ohio State University. Fellow, Molecular Immunology
2000 - 2001 Daniel Valentino, The Ohio State University. Roessler Foundation Scholar
2000 - 2001 Gerad Abood, The Ohio State University. Roessler Foundation Scholar
2001 - 2002 Jennifer Biber, The Ohio State University. Graduate Program, Molec. Immunol., dropped on request
2001 - 2003 Brian Badgwell,, The Ohio State University. PGY 3, Department of Surgery
2000 - 2004 Robin Parihar,, The Ohio State University. Graduated 2004. Graduate Program, Molecular Immunology
2003 - 2004 Michael Go,, The Ohio State University. PGY 3, Department of Surgery
2001 - 2005 Gregory Lesinski, The Ohio State University. Fellow, Human Cancer Genetics
2004 - 2006 Kimberly Varkar,, The Ohio State University. PGY 9, Department of Surgery, T32 fellow
2005 - 2006 Llloyd Brown,, The Ohio State University. PGY 3, Department of Surgery
2003 - 2007 Julie Roda,, The Ohio State University. Graduated 2007. Graduate Program, IBGP
2003 - 2007 Jason Zimmerer,, The Ohio State University. Graduated 2007. Graduate Program, IBGP
2006 - 2007 Natalie Jones,, The Ohio State University. PGY 3, Department of Surgery
2006 - 2008 Aruna Mani,, The Ohio State University. PGY 5, Department of Surgery
2005 - 2010 Ene Raig,, The Ohio State University. Graduated 2010. The MD/PhD Medical Scientist Training Program
2008 - 2011 Bethany Mundy, The Ohio State University. Graduated 2011. Graduate Program, IBGP
2009 - 2013 Cristina Jaime-Ramirez, The Ohio State University. Graduated 2013. Graduate Program, IBGP
 

Licenses

1987 - present Diplomate: National Board of Medical Examiners
1992 - present Diplomate: American Board of Surgery
2002 - present Recertification: American Board of Surgery
2012 - present Recertification: American Board of Surgery
 

Chapters in Books

Cellular adoptive immunotherapy with natural killer cells

Animal models of malignant melanoma

Novel cytokines in the treatment of malignancies.

Interleukin-6.

The type I intereron family

The role of natural killer cells in innate immunity

Animal models of malignant melanoma

Interferon-alpha as a Vaccine Adjuvant

 

Conferences

Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer

Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to IFN-alpha adjuvant therapy

Flow cytometric monitoring of Jak-STAT signal transduction within melanoma cells

Expression of pro-angiogenic factors in malignant melanoma and their regulation by low-dose interferon-alpha

Impaired immunity in breast cancer patients with high levels of psychologic stress is associated with alterations in killer immunoglobulin-like receptors

A phase I trial of interleukin-12 with trastuzumab and paclitaxel for HER2-overexpressing malignancies

Enhanced in vitro and in vivo anti-tumor activity of bortezomib (Velcadeo (R), PS-341) when administered with interferon-alpha

A novel flow cytometric assay for measurement of phosphorylated STAT5 in peripheral blood mommuclear cells of melanoma patients receiving interleukin-2

A role for antigen presenting cells (APC) in post-transplant lymphoproliferative disorder (PTLD).

Phase I trial of interleukin-12 with trastuzumab and paclitaxel in HER2-overexpressing malignancies.

Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects

A phase II trial of bevacizumab with or without low-dose interferon-alpha in patients with metastatic malignant melanoma

Use of nanochannel membranes to regulate the release of cytokines from biodegradable reservoirs

Nanoporous delivery devices based on biodegradable polymers for constant drug release

IL-21 promotes apoptosis through induction of the BH3 only protein bim and enhacnes direct and innate immune-promoted death of chronic lymphocytic leukemia cells

IL-29 Induces Jak-STAT Signal Transduction and can Synergize With Temozolomide and Bortezomib in Human Melanoma Cell Lines

Cytokines Enhance the Anti-tumor Effects of Folate Conjugated Immunoglobulin

Global Gene Expression in Activated CD56(DIM)CD16(+) Human NK Cells

STAT3-specific Small-molecule Curcumin Analogs FLLL32 and FLLL62 Induce Apoptosis and Enhance the Direct Antitumor Effect of Interferons

SOCIAL SUPPORT PREDICTS INFLAMMATION, PAIN, AND DEPRESSIVE SYMPTOMS: LONGITUDINAL RELATIONSHIPS AMONG BREAST CANCER SURVIVORS

ATTACHMENT ANXIETY IS RELATED TO EPSTEIN-BARR VIRUS LATENCY WHILE UNDERGOING TESTING FOR BREAST OR COLON CANCER, AS WELL AS ONE YEAR LATER

 

Degrees

1982 B.S., University of California Irvine

1986 M.D., University of Southern California

 

Honors

1982 - present Phi Beta Kappa National Honor Society. University of California, Irvine.
1982 - present Dean's Academic Achievement and Service Award. University of California, Irvine.
1989 - present L.T. Fuerbusch Award for Cancer Research. University of California, Irvine.
1994 - present Merit Award. American Society of Clinical Oncology.
1995 - present Outstanding Research Paper Award. Roswell Park Cancer Institute.
1995 - present Young Investigator Award. American Society of Clinical Oncology.
1998 - present Cancer Research Award. The Valvano Foundation.
1999 - present Institutional Research Grant. American Cancer Society.
2004 - present Elected member. American Society of Clinical Investigation.
2005 - present Excellence in Teaching Award. Department of Surgery.
2005 - 2015 America's Best Doctors. U.S. News & World Report.
 

Journal Articles

.

 

Presentations

Recent Developments in Cytokine Therapy for Malignant Melanoma

Therapy of Breast Cancer with Herceptin

In vitro/In vivo studies of IL-12 in Combination with Interferon-Alpha

Immunotherapy of Melanoma: Inception, Impact, and Implications

The Use of Biologics with Herceptin

The Mechanism of IFN-alpha in Melanoma: Clues to Rationale Therapy

A Phase I Trial of IL-12 and Herceptin: Update and Clinical Correlates

Herceptin with Cytokines

Laborator Correlates for a Phase I Trial of IL-12 and Interferon-Alpha

Breast Cancer 2002: Genetics, biologics, and minimally invasive surgery

Therapy of Cancer with Antiobodies and Biologics

A Phase I Trial of IL-12 and IFN-Alpha: Update and Clinical Correlates

Therapy of Malignant Melanoma with an Anti-VEGF antibody

IFN-a with CEA TRICOM Vaccine

Controlled release of immunologic compounds from a nanomembrane

Laboratory Correlates for a Phase I Trial of Bevacizumab and Interferon-Alpha

Suppressors of Cytokine Signaling: A pair of SOCS

Controversaries in Clinical Research

Protesome Inhibition in Clinical Practice

Interferons and Cancer

Adventures in Tissue Acquisition

Update on Bevacizumab for Metastatic Melanoma

Immune Suppressor Cells

Clinical trials.